Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882529 | 0.81 | GAA (0.64) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL4874699 | 0.79 | GAA (0.60) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL4880867 | 0.77 | GAA (0.58) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL22719667 | 0.77 | TGM2 (0.75) | GAAEPHX2EPHX1TGM2 | |
| SCHEMBL3964869 | 0.76 | EPHX1 (0.75) | GAAMEN1KMT2AEPHX2EPHX1 | |
| SCHEMBL28256062 | 0.75 | GAA (0.66) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL4872374 | 0.74 | EPHX2 (0.71) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL23497847 | 0.74 | EPHX2 (0.66) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL19011426 | 0.73 | LMNA (0.66) | LMNAMEN1KMT2AALDH1A1EPHX2 | |
| SCHEMBL4011697 | 0.73 | EPHX1 (0.78) | LMNAGAAMEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | LMNA 1843/4885GAA 914/4885MEN1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.